Compare Bristol-Myers Squibb Co (BMY) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Hilton Hotels Corporation Common Stock — how do they compare? Bristol-Myers Squibb Co trades at $58.7 (market cap $116.30B), while Hilton Hotels Corporation Common Stock trades at $327.73 (market cap $74.18B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | HLT | |
|---|---|---|
Market Cap | $116.30B | $74.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $350.22 |
52-Week Low | $42.60 | $256.75 |
Enterprise Value | $152.24B | $86.68B |
Dividend Yield | 4.42% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Hilton Worldwide (HLT) trades at $322.45, down 3.88% amid bearish technical signals, though it maintains strong fundamentals with consistent earnings beats and revenue growth to $12.04B in 2025. Analyst consensus remains bullish with a $340.50 price target, supported by 55% buy ratings. Recent news highlights brand campaigns and renovations, while financials show robust cash flow but rising debt levels.
The stock offers upside to analyst targets but faces near-term technical pressure and leverage concerns. Investment appeal hinges on execution of growth initiatives and debt management, with risks including economic sensitivity and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
